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A B S T R A C T
Neuropsychiatric disorders appear in about 70% of the patients diagnosed with systemic lupus erythematosus (SLE).
The aim of this study was to evaluate morphological and functional abnormalities of central nervous system (CNS) in
SLE patients with neuropsychiatric manifestations (NP) of disease by testing their relationship. We tested 10 patients (9
females, 1 male) with clinical manifestations of neuropsychiatric systemic lupus erythematosus (NP-SLE). That means
clinical evaluation of symptoms, standard immunoserological tests, electroencephalogram (EEG), component of audio-
-evoked potentials P300, MMPI-202 test, Rey Complex Test and magnetic resonance imaging (MRI). MRI abnormalities
were seen in all of our patients, while in 9 patients abnormalities in neuropsychological and neurophysiologic tests have
been proved. The most common structural brain change, detected by MRI, was cortical atrophy (in 8 out of 10 patients).
According to revised classification of the American College of Rheumatology (ACR) NP-SLE, the most frequent disorder
was cognitive dysfunction (in 9 out of 10 patients). Cortical atrophic brain changes have been established in 7 out of 9 pa-
tients with cognitive dysfunction. Because of already known correlation of cortical atrophy with cognitive dysfunction in
SLE patients, without neuropsychiatric manifestation, we can conclude that neuropsychological examination is required
in every patient with systemic lupus erythematosus.
Key words: systemic lupus erythematosus, neuropsychiatric systemic lupus erythematosus, magnetic resonance im-
aging, cognitive dysfunction
Introduction
SLE is chronic multi-systemic disease of unknown eti-
ology. The basic pathogenic mechanism of the disease is
production of the whole spectrum of antibodies and im-
mune complexes, as well as the disorder of suppression in
their production and elimination. Clinical presentation
can vary from milder skin and joint manifestations to life
threatening disorders, such as kidney and heart malfunc-
tion and hematological and neuropsychiatric disturban-
ce1. Diagnosis has been based on positive criteria of the
ACR-four positive out of eleven criteria2.
Neuropsychiatric disorders appear in about 70% of
the patients with SLE. They can be manifested as subcli-
nical disorders in cognitive functions (reasoning, think-
ing, memory, studying, orientation etc) or as serious clini-
cal manifestations, such as stroke, aseptic meningitis
and transverse myelitis3,4.
Neuropsychiatric disorders are likely to be primary to
genesis of SLE or to other concomitant conditions, which
frequently occur in SLE patients. These conditions in-
clude uremia, hypertension, infection, Libman-Sack`s
endocarditis, as well as those as a result of corticosteroid
and immunosuppressive therapy. The primary NP-SLE
is immunologically mediated disease with consequential
vasculopathy and coagulopathy (antiphospholipid anti-
bodies) and vasculitis. However, frequently we find ele-
ments of vasculopathy and vasculitis concurrently with
concomitant conditions3–7. With reference to diversity of
clinical presentation, NP-SLE represents a major diag-
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nostic and therapy problem8. That is why more diagnos-
tic simultaneous procedures are usually applied. Most
frequently used techniques are computed tomography
(CT), magnetic angiography (MRA), digital subtraction
angiography (DSA), single photon emission computed to-
mography (SPECT) and definitely MRI.
Conventional MRI, providing opportunity for a de-
tailed description of structural changes in NP-SLE, has
become a »golden« standard in its diagnostics. Structural
changes can be found in 25–50% of patients without
NP-SLE symptoms and in 33–100% of those with clinical
manifestations9–17. Beside its diagnostic usefulness, this
method can be advantageous in evaluation and monitor-
ing therapy outcome in NP-SLE patients15,18.
Nevertheless, a considerable number of patients diag-
nosed with SLE have cognitive disorders, according to
ACR criteria, with absence of neurological or psychiatric
symptoms19. Namely, using common radiological diag-
nostic procedures (CT or MRI), structural changes in
those patients sometimes remain undetected, so the fun-
ctional deterioration of central nervous system (CNS) is
possible to detect only through various clinical neuropsy-
chological tests. In previous studies association of corti-
cal atrophy and cerebral attacks with cognitive disorders
was mentioned4,20–22.
In spite of an increasing number of sophisticated di-
agnostic procedures, there still are significant difficulties
in defining diagnostic criteria and the treatment of NP-
-SLE. Revised ACR nomenclature NP-SLE which includes
nineteen different neuropsychiatric syndromes should
make classification and diagnostic of neuropsychiatric
disorders in SLE easier, and therapy procedures uni-
form23. So far only a few prospective controlled studies
have been issued, based on new ACR criteria of NP-
-SLE3,24–28.
In the study we investigated 10 patients (9 females, 1
male) with clinical manifestations of neuropsychiatric
systemic lupus erythematosus (NP-SLE). That includes
clinical evaluation of symptoms, standard immunosero-
logical tests, electroencephalogram (EEG), component of
audio-evoked potentials P300, MMPI-202 test, Rey Com-
plex Test and magnetic resonance imaging (MRI). The
aim of the study was to evaluate morphological and func-
tional abnormalities of central nervous system (CNS) in
tested SLE patients with neuropsychiatric manifestation
(NP) and their relationship.
Patients and Methods
Our pilot study included 10 (9 females and 1 male)
SLE patients (all of them fulfilled at least four of the
eleven ACR criteria for the classification of SLE2) hospi-
talized in our Clinic with neuropsychiatric SLE manifes-
tations. These clinical manifestations were as follows: a
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TABLE 1
DEMOGRAPHIC DATA AND CLINICAL CHARACTERISTICS OF NP-SLE PATIENTS








1 KR 43 F 0.5 0.1 convulsions
Methylprednisolone 8 mg/day
Chloroquine 250 mg/day





3 @P 24 M 0.3 0.1 psychosis Methylprednisolone 32 mg/day









6 MG 62 F 5 1.5 headache
Methylprednisolone 6 mg/day
Methotrexate 10 mg/week






8 IB 42 F 10 0.4 headache Chloroquine 250 mg/day






10 MK 50 F 9 0 convulsions
Methylprednisolone 12 mg/day
Warfarin 7.5 mg/day
F – female, M – male, TIA – transient ischemic attack, ASA – acetylsalicylic acid
protracted headache, transitory ischemic attack, stroke,
convulsions, and weakness of lower limbs, psychosis,
anxiety disorders and depression (Table 1). The whole
SLE patients were selected by examination of rheuma-
tologist, neurologist and psychiatrist. We excluded pa-
tients with positive history of neurological or psychiatric
disease before the first SLE presentation. NP-SLE classi-
fication has been based on revised ACR Ad Hoc Commit-
tee NP nomenclature22. In Table 1 we evaluated all the
therapy the patients were taking before hospitalization.
Disease activity was evaluated using the ECLAM index29.
Serological profile, important for our follow-up is pre-
sented in Table 2.
Antinuclear antibodies were detected by indirect immu-
nofluorescence using HEp-2 cell as substrate30. Level of
complement components C3 and C4 was measured by la-
ser nephelometry (Behring Pro Spec nephelometer)31.
Lupus anticoagulant (LA) was determined by coagulo-
metric method on coagulation analysis machine BCT32.
Anticardiolipin antibodies (aCL), anti-proteinase 3 (anti-
-PR3/c-ANCA), anti-mieloperoxidase (anti-MPO/p-ANCA)
and anti-dsDNA antibody were detected by ELISA33–35.
Electrophysiological tests included electroencephalo-
gram (EEG), as well as the component of audio-evoked
potentials P30036,37.
Neuropsychological examinations included: 1) MMPI-
-202 test which provides an insight into intrapsychic pa-
tient’s dynamic, so called personality profile, 2) Complex
Figure Test (CFT) or Rey Complex Test which detects
perceptive-mnemonic capabilities as important cognitive
functions. The test values are expressed in centiles38,39.
Patients were tested individually by an experienced psy-
chiatrist and a psychologist who were unaware of the
clinical data.
MRI was performed on EPIOS 5 unit, Shimatzu, 0.5 T
using standard spin-echo technique (19 layers of 5 mm
thickness, with sagital, transversal and coronary cross-
-section). Measuring times T1 (TR/TE = 779/22) and T2
(TR/TE = 4935/88) and proton density were applied to
obtain brain analysis in all patients. Paramagnetic con-
trast-agent was employed likewise. MRI was analyzed by
a neuroradiologist who was unaware of the clinical data.
Results
Demographics
We analyzed ten SLE patients (9 female, 1 male) who
have been hospitalized because of neuropsychiatric man-
ifestation of disease, the average age was 43.3 (from 24 to
62). The average duration of SLE was 7.7 years (from 0.3
to 19) with duration of neuropsychiatric manifestation of
about 1.1 year (from 0 to 8; Table 1). The activity of the
disease was expressed through ECLAM scale with a
value of approximately 6.6 (from 3 to 10; Table2).
Nine patients were treated with glucocorticoid at a
dose less than 0.5 mg/kg/per day. Four female patients
were treated with antimalarial agents at an average dose
of 250 mg a day, one female patient was receiving aza-
thioprine at an average dose of 100 mg daily, and two fe-
male patients were treated with methotrexate at an aver-
age dose of 10 mg per week.
Neuropsychiatric manifestations in two female pa-
tients were convulsions, psychotic behavior in one male
patient, anxiety disorders in one female patient, head-
ache in two female patients, hemiparesis in one female
patient, depression in one female patient. Combined dis-
orders of weakness in lower limbs and mood disorder was
diagnosed in one female patient, TIA and anxiety was
found in one female patient (Table 1).
When the patients were classified according to new
ACR criteria of NP-SLE, the most common syndrome
was cognitive dysfunction (Table 3).
Serologic profile
In six patients lowered levels of complement compo-
nents C3 and C4 were found. Two female patients previ-
ously diagnosed as secondary antiphospholipid syndrome
had high levels of aCL antibodies The high level of LA
was found in one of them. In the case of six patients the
high level of anti-dsDNA was proved.
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TABLE 2
SEROLOGICAL INDICATORS IN NP-SLE PATIENTS
Patient ECLAM ANA C3 C4 LaC aCL antids DNA ANCA MPO/PR3
1 KR 4 1:80 0.927 0.183 1.26 5 76 1/1
2 MV 9 1:80 0.48 0.084 1.17 2 52 2/2
3 @P 10 1:160 0.24 0.01 0.86 4 >1000 6/3
4 BI 5 1:20 0.724 0.0864 2.4 32.48 174 0/0
5 V[ 9 1:160 0.423 0.0855 1.22 2 764 2/1
6 MG 3 negative 1.23 0.37 0.9 5 51 2/2
7 NM 6 1:160 1.090 0.160 0.9 4 461 3/1
8 IB 4 1:40 0.732 0.124 0.76 5 8 1/2
9 ABK 5 1:160 1.47 0.146 1.1 9 525 1/2
10 MK 5 1:40 0.722 0.0809 1.1 23 58 1/1



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































In one patient the level of ANCA-MPO was slightly
higher, while the levels of ANCA-PR3 were close to refer-
ence values in all tested patients (Table 2).
EEG
In five female patients we found non specific diffuse
paroxysmal disrhytmic changes on EEG, while in two fe-
male patients diffuse and parietotemporal focal changes
were shown. Normal EEG was registered in three pa-
tients (Table 3).
P 300
A disorder of amplitude and latency extension P 300
of audio-evoked potential was observed in eight patients
(Table 3).
Neuropsychological examinations
By means of MMPI-202 test (Figure 1) as well as Rey I
(perceptive) and Rey II (mnemonic) tests (Figures 2, 2a
and 2b), anxiety disorders were found in five patients,
cognitive dysfunctions in nine patients (two very seri-
ous), mood disorder (manic type) in one female patient
and psychosis in two patients (Table 3).
MRI
The most common change, discovered on standard
MRI unit, was cortical atrophy in eight patients (patients
1,3–8,10). Dominant changes observable in three pa-
tients (patients 6,7,10) were temporoparietal, in two pa-
tients (patients 4,8) parietal, in one patient (patient 3)
parietooccipital and in one female patient (patient 1) in
fissure Silvy region on both sides. In two young patients
with different disease duration (patients 3 and 5), serious
atrophic changes, inappropriate to their age, were dis-
covered. Both patients showed symptoms of psychosis
during neuropsychological tests.
Dilatation of basal cisterna and occipital horns was
observed in three patients (patients 1, 5, 7). Hyper-inten-
sity signals in measuring images T2 and T1 (Figure 3, 3a
and 3b) were established in four patients (patients 4, 7, 9,
10). Lesions were multiple, of different localization, in-
cluding both, white and grey matters, which corresponds
to lacunar vascular lesion. The foci of demyelinization
process, diffusely paraventricular of questionable etiol-
ogy, were found in one patient (patient 2; Table 3). Two
female patients with hyper-intensive changes in T2 mea-
suring time, had the high level anticardiolipin antibody.
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Fig. 1. MMPI-202 of one of the patients with NP-SLE.
Discussion
Our study included 10 patients suffering from NP-SLE,
who underwent neuroradiological, neurophysiologic and
neuropsychological examinations. All of them had chan-
ges on MRI, while nine of them showed aberrations in
neurophysiologic and neuropsychological tests.
Infarct of cortex and/or white matter, sub-cortical and
periventricular lesions of white substance and cortical
atrophy were most commonly described changes, de-
tected by MRI15,16,18,40–44. In a majority of previous stud-
ies multiple slight punctiform vascular ischemic lesions
were established as a common change11,15,18,44–47. Unlike
those studies, the most common change in our study was
cortical atrophic change, found in 8 out of 10 patients.
Atrophic changes, inappropriate to age, were found in
two young patients (24 years old). One patient has been
suffering from SLE for 10 years and the other for 3
months. Both of them were treated with glucocorticoid
but in quite different longines, with the last dosage less
than 0.5mg/kg/daily. Beside cognitive dysfunction, both
patients presented the symptoms of psychosis during
neuropsychological tests. Although it is hard to distin-
guish how much glucocorticoid therapy influenced the
occurrence of the neuropsychiatric disorders, it is inter-
esting that in our patients one was receiving the glu-
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a) b) c)
Fig. 3. a) Transverse T2-weighted MRI with serious cortical atrophic changes especially parietotemporal with dilatation of occipital horns. b)




Fig. 2. a) CFT (Complex Figure Test) or »Rey Complex Test«. b)
Cognitive dysfunction – CFT (Complex Figure Test). c) Serious
cognitive dysfunction – CFT (Complex Figure Test).
cocortocoid therapy for 3 months, while the other was
taking it at intervals for about 6 years, at an average dose
of 8 mg per day.
In 5 of 10 patients punctiform lesions (hyper-inten-
sity signals in T2 and T1 measuring time), dilatation of
basal cisterna and occipital horns, foci of demyelinization
process were also detected by means of MRI.
According to ACR classification of NP-SLE, the most
common disorder has been cognitive dysfunction (in 9
out of 10 patients). The disorder is related to percep-
tive-mnemonic function impairments, as well as to au-
dio-extended latency of cognitive evoked potential.
Cognitive disorders, such as attention and visual-spa-
tial abilities, were already described in SLE patients,
even without clinical manifestations of NP-SLE44.48,49.
Beside lupus psychosis, several studies described some
other psychiatric changes, the prevalence of which is de-
pendent on SLE patient’s structure, as well as on stan-
dardization of criteria used in diagnostics50,51.
In majority of our patients, moderate cognitive dys-
functions were observable, while a serious cognitive dis-
order was found in two patients.
In seven out of nine patients suffering from cognitive
dysfunction, cortical atrophic brain changes were found
on MRI. This result is in accordance with certain stu-
dies21,22 which stated that cortical brain atrophy and ce-
rebral strokes were the only features of SLE significantly
associated with cognitive disorders.
That suggests the conclusion that the most common
change in our NP-SLE patients, found on MRI was corti-
cal brain atrophy associated with cognitive dysfunction.
Although study was performed on small number of
patients, strongly association of cortical brain atrophy
with cognitive dysfunction suggested that all SLE pa-
tients required neuropsychological examination as a pos-
sible predictor of structural brain changes.
Note: ECLAM index for the assessment of disease activity in SLE pa-
tients include neuropsychiatric manifestation. In some paper published
current contens indexed journal that we citated in our work was used
ECLAM index44.
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NEUROPSIHIJATRIJSKI PREME]AJI U BOLESNIKA SA SISTEMSKIM LUPUSOM PREMA
REVIDIRANIM KRITERIJIMA AMERI^KOG REUMATOLO[KOG DRU[TVA
S A @ E T A K
Neuropsihijatrijski poreme}aji se javljaju u oko 70% bolesnika sa sistemskim lupus eritematodesom (SLE). Cilj ove
studije je bio utvrditi strukturne i funkcionalne poreme}aje sredi{njeg `iv~anog sustava u bolesnika sa sistemskim
lupus eritematozusom s neuropsihijatrijskim manifestacijama i njihovu povezanost. Analizirali smo 10 bolesnika (9
`ena, 1 mu{karac) s klini~kim manifestacijama neuropsihijatrijskog sistemskog lupus eritematodesa (NP-SLE). Uz kli-
ni~ku procjenu i odre|ivanje standardnih imunoserolo{kih parametara, svim bolesnicima je u~injen elektroencefalo-
gram, P300 audio-evocirani potencijali, MMPI-202 test, Rey Complex test i magnetska rezonanca (MR) mozga. Pro-
mjene na MR su na|ene u svih bolesnika, dok su u devet bolesnika na|eni poreme}aji u neuropsiholo{kim i neurofiziolo{kim
testovima. Naj~e{}a strukturna promjena mozga utvr|ena magnetskom rezonancom je bila kortikalna atrofija (u 8 od 10
bolesnika). Prema revidiranoj klasifikaciji Ameri~kog reumatolo{kog dru{tva (ACR) NP-SLE-a naj~e{}i poreme}aj je
bio kognitivna disfunkcija (u 9 od 10 bolesnika). U sedam od devet bolesnika s kognitivnom disfunkcijom su utvr|ene
kortikalne atrofi~ke promjene mozga. S obzirom da se kognitivna disfunkcija u bolesnika sa SLE-om mo`e na}i bez
neuropsihijatrijskih manifestacija te postojanje korelacije kortikalne atrofije s kognitivnom disfunkcijom, mo`emo zak-
lju~iti da je neuropsiholo{ko ispitivanje potrebno provesti u svih bolesnika sa sistemskim lupus eritematozusom.
A. Bu}a et al.: Diagnostic and Clinical Features of NP-SLE, Coll. Antropol. 33 (2009) 1: 281–288
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